China Nuokang Bio-Pharmaceutical Inc. Announces Change in CFO
15 Giugno 2012 - 2:00PM
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or
the "Company"), a leading China-based biopharmaceutical company
focused on the research, development, manufacture, marketing and
sales of hospital-based medical products, today announced that
Robert Tianruo Pu, the chief financial officer of the Company, has
tendered his resignation for personal reasons, effective June 30,
2012. Felix Chungfai Wong, currently the Company's finance
director, will replace Mr. Pu to serve as the chief financial
officer. Upon his resignation, Mr. Pu will remain with the
Company as a consultant.
"Mr. Pu has made significant contributions to Nuokang's growth
and development since he joined in September 2008. We thank him for
his leadership and dedication to the Company. We wish him all the
best in his future endeavors," commented Mr. Baizhong Xue, the
Company's chairman and chief executive officer.
Felix Chungfai Wong joined Nuokang in February 2012 as its
finance director. Mr. Wong has three decades of experience in
finance, management and accounting in the U.S. and Greater China.
He joined Nuokang from ITT Corporation, a company listed on the New
York Stock Exchange, where he held various senior financial
management positions. Prior to that, he held various senior finance
positions across a broad range of industries, including finance
manager of Roche (China) Investment Ltd., one of the world's
leading pharmaceutical and diagnostics firms. He also has a decade
of auditing experience in large multinational accounting firms in
Hong Kong and Singapore. Mr. Wong graduated from the
Accountancy Faculty of the Hong Kong Polytechnic University and is
a member of the Hong Kong Institute of Certified Public
Accountants, the Association of Chartered Certified Accountants and
the Institute of Chartered Accountants in England &
Wales.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research,
development, manufacture, marketing and sales of hospital-based
medical products. The Company provides a diversified portfolio of
products across more than 4,200 hospitals in China. Nuokang's
principal products include (1) Baquting®, China's leading
hemocoagulase product by market share, (2) Kaitong®, a lipid
emulsion alprostadil product for the treatment of peripheral
vascular diseases, cardiocerebral microcirculation disorders and
post-surgery thrombosis, and (3) Alpha Lipoic Acid Capsule, or ALA,
an antioxidant product that addresses diabetic neuropathy. The
Company's product pipeline includes product candidates under
development in hematological, cardiovascular and cerebrovascular
disease diagnosis, treatment and prevention. Please visit
www.nkbp.com for more information.
Safe-Harbor Statement
This press release contains statements of a forward-looking
nature. These statements are made under the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including certain plans, expectations, goals, and projections,
which are subject to numerous assumptions, risks, and
uncertainties. These forward-looking statements may include, but
are not limited to, statements containing words such as "may,"
"could," "would," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," "expects," "intends" and "future" or
similar expressions. Among other things, the statements relating to
the Company's expected progress on the product portfolio and future
financial results may contain forward-looking statements. These
forward-looking statements speak only as of the date of this press
release and are subject to change at any time. These
forward-looking statements are based upon management's current
expectations and are subject to a number of risks, uncertainties
and contingencies, many of which are beyond the Company's control
that may cause actual results, levels of activity, performance or
achievements to differ materially from any future results, levels
of activity, performance or achievements expressed or implied by
such forward-looking statements. The Company's actual results could
differ materially from those contained in the forward-looking
statements due to a number of factors, including those described
under the heading "Risk Factors" in the Company's filings with the
U.S. Securities and Exchange Commission, including its annual
report on Form 20-F.
CONTACT: China Nuokang Bio-Pharmaceutical Inc.
Mr. Steven Duan
Vice President of Investor Relations
Email: dsz@nkbp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516 or (646) 405-5180
Email: robert.koepp@icrinc.com
Grafico Azioni China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Storico
Da Lug 2023 a Lug 2024